Last reviewed · How we verify

Analgesic Agent

Alliance for Clinical Trials in Oncology · Phase 3 active Small molecule

An analgesic agent that reduces pain through modulation of pain signaling pathways.

An analgesic agent that reduces pain through modulation of pain signaling pathways. Used for Cancer-related pain (phase 3 development).

At a glance

Generic nameAnalgesic Agent
SponsorAlliance for Clinical Trials in Oncology
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

The specific mechanism is not detailed in the provided information. As a general analgesic in phase 3 development by the Alliance for Clinical Trials in Oncology, it likely targets pain management in cancer patients, potentially through neuropathic pain reduction, inflammatory pathway inhibition, or opioid receptor modulation. Further characterization would require additional clinical trial data.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: